Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679, are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. This action helps relax blood vessels in the lungs, lowering pulmonary blood pressure and improving exercise capacity. Selexipag is often prescribed to delay disease progression and reduce the risk of hospitalization in PAH patients, making it a significant therapeutic option for long-term management.
Parent: Selexipag
Parent: Selexipag
Parent: Selexipag
Parent: Selexipag
Parent: Selexipag
Parent: Selexipag
Parent: Selexipag
![4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-butanol](https://veeprho.com/wp-content/uploads/2022/11/4-5-6-Diphenyl-2-pyrazinyl-1-methylethyl-amino-1-butanol.png "4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-butanol")
Parent: Selexipag
During the production and storage of Selexipag, impurities may form, and these must be controlled to ensure the drug’s safety and efficacy. Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), set guidelines for permissible impurity levels in Selexipag formulations.
Selexipag works by activating prostacyclin receptors, which helps relax and dilate blood vessels in the lungs. This action lowers pulmonary blood pressure and reduces strain on the heart, helping improve exercise capacity and slow disease progression in patients with pulmonary arterial hypertension.
The half-life of Selexipag itself is approximately 0.8 to 2.5 hours. However, its active metabolite has a longer half-life of around 6.2 to 13.5 hours, which allows for twice-daily dosing in managing pulmonary arterial hypertension.
Yes, Selexipag acts as a vasodilator. By stimulating prostacyclin receptors, it helps relax the blood vessels in the lungs, which lowers blood pressure in the pulmonary arteries and improves blood flow.
The composition of Selexipag includes the active ingredient Selexipag itself, which is a selective prostacyclin receptor agonist. The tablet formulation also includes various inactive ingredients (excipients) that stabilize the medication and aid in absorption. Specific excipients may vary by manufacturer, so it’s essential to consult the medication’s labeling for detailed composition.
